Poor
Not Aligned
Patient Risk:
High
Summary
Most claims evaluated (concerning aspirin + naproxen interaction, NSAIDs, ulcers/platelets/kidney effects, acetaminophen comparisons, and timing-dose rules) are not supported by the provided FDA label excerpts for aspirin and extended-release dipyridamole. Several safety/interaction assertions appear to mix information about different drug combinations that are not described in the label excerpts. Only general concepts like increased bleeding risk with coagulation-affecting drugs are directionally supported, but the specific aspirin+naproxen content is unsupported.
Category Scores
Accurate Statements
Aspirin and Extended-Release Dipyridamole Capsules increase the risk of bleeding.
Section 5.1 (Risk of Bleeding): “Aspirin and extended-release dipyridamole increases the risk of bleeding.”
Risk of bleeding is increased with other drugs that increase bleeding risk (e.g., anticoagulants/antiplatelets; chronic use of NSAIDs).
Section 5.1: “Risk factors for bleeding include… other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents… and chronic use of NSAIDs)”.
Unsupported Statements
Taking aspirin and naproxen together is usually not recommended unless a clinician specifically tells you to do so.
Provided label excerpts do not discuss naproxen or recommend avoiding aspirin+naproxen combination.
Aspirin and naproxen are both NSAIDs.
Provided label excerpts do not characterize naproxen as an NSAID or discuss naproxen; the label excerpts are for aspirin + extended-release dipyridamole.
Combining aspirin and naproxen increases the risk of stomach bleeding.
Label excerpts only state bleeding risk with aspirin + extended-release dipyridamole generally and with coagulation-impacting drugs; they do not mention naproxen or stomach-specific bleeding with naproxen.
Combining aspirin and naproxen increases the risk of ulcers.
No ulcers/ulcer risk statements tied to aspirin+naproxen are present in the provided label excerpts.
Combining aspirin and naproxen increases kidney-related risk.
Provided label excerpts mention avoiding aspirin in severe renal failure (GFR <10 mL/min) but do not discuss naproxen or combined kidney risk with naproxen.
Both aspirin and naproxen can irritate the stomach lining.
No such statement is supported by the provided excerpts.
Both aspirin and naproxen can affect platelet function.
While the label excerpt describes additive antiplatelet effects of dipyridamole and aspirin, it does not discuss naproxen or platelet effects of naproxen.
Both aspirin and naproxen can affect kidney blood flow.
Not present in the provided label excerpts.
The bleeding and ulcer risk increases when aspirin and naproxen are used together.
Naproxen-specific combined bleeding/ulcer risk is not supported in provided excerpts.
If naproxen is taken incorrectly, it may interfere with how well aspirin blocks platelet activity.
No naproxen/aspirin timing interaction is provided in the provided label excerpts; the label excerpt states no significant interactions between aspirin and dipyridamole (not naproxen).
This potential interference is especially important for people who take aspirin for heart or stroke prevention.
Not supported; label excerpts do not discuss aspirin+naproxen interference or special timing considerations for heart/stroke prevention.
Naproxen can reduce the benefit of low-dose aspirin used for cardiovascular prevention.
No naproxen-specific claim appears in the provided label excerpts.
The interaction between aspirin and naproxen depends on timing and dose.
No naproxen-specific timing/dose interaction guidance in the provided label excerpts.
For people using aspirin for cardiovascular prevention, clinicians often try to manage NSAID choice and timing to preserve aspirin’s antiplatelet effect while controlling pain or inflammation.
Not supported by provided label excerpts.
If a person has been taking aspirin and naproxen together, gastrointestinal bleeding signs to watch for include black/tarry stools.
The provided label excerpts do not list specific GI bleeding signs/symptoms for the aspirin+naproxen combination.
If a person has been taking aspirin and naproxen together, gastrointestinal bleeding signs to watch for include vomiting blood.
Not supported by provided label excerpts.
If a person has been taking aspirin and naproxen together, gastrointestinal bleeding signs to watch for include severe stomach pain.
Not supported by provided label excerpts.
If a person has been taking aspirin and naproxen together, kidney-related symptoms to watch for include reduced urination.
Not supported by provided label excerpts.
If a person has been taking aspirin and naproxen together, kidney-related symptoms to watch for include swelling.
Not supported by provided label excerpts.
If a person has been taking aspirin and naproxen together, kidney-related symptoms to watch for include sudden shortness of breath.
Not supported by provided label excerpts.
If signs of gastrointestinal bleeding or kidney-related symptoms occur while taking both aspirin and naproxen, urgent medical care should be sought.
Not supported by provided label excerpts.
In many cases, people are advised to avoid adding another NSAID (like naproxen) on top of aspirin unless their prescriber approves.
Not supported by provided label excerpts for the labeled product.
Acetaminophen (paracetamol) is used for pain/fever.
Not addressed in the provided label excerpts.
Acetaminophen does not work like NSAIDs.
Not addressed in the provided label excerpts.
Acetaminophen generally has a lower risk of stomach bleeding.
Not addressed in the provided label excerpts.
Whether acetaminophen is appropriate depends on the person’s medical history.
Not addressed in the provided label excerpts.
Medical advice should be obtained before using naproxen with aspirin if the person takes aspirin for a heart attack, stroke, or stent.
Naproxen + aspirin advice tied to those indications is not supported by provided label excerpts.
Medical advice should be obtained before using naproxen with aspirin if the person has a history of ulcers or GI bleeding.
Not supported by provided label excerpts.
Medical advice should be obtained before using naproxen with aspirin if the person has kidney disease or heart failure.
Label excerpts include avoidance in severe renal failure (GFR <10 mL/min), but do not provide naproxen-specific advice for kidney disease/heart failure.
Medical advice should be obtained before using naproxen with aspirin if the person uses blood thinners (like warfarin, apixaban, rivaroxaban) or corticosteroids.
Label excerpts address increased bleeding risk with anticoagulants/antiplatelet agents generally, but do not discuss naproxen or specifically advise before using naproxen.
Medical advice should be obtained before using naproxen with aspirin if the person has high bleeding risk or takes multiple NSAIDs.
Not supported for naproxen-specific combination.
If a doctor allows both aspirin and naproxen, naproxen should be taken at a specific time relative to aspirin.
No naproxen timing guidance is provided in the provided label excerpts.
If a doctor allows both aspirin and naproxen, the lowest effective naproxen dose for the shortest duration should be used.
Not provided in the label excerpts.
Timing and dose details can change the risk profile of taking aspirin and naproxen.
Not supported by provided label excerpts.
Contradictions
Important Omissions
Product-specific dosing/administration instructions for aspirin and extended-release dipyridamole (e.g., one capsule twice daily morning/evening; swallow whole; can be administered with or without food; not interchangeable with individual components).
Importance:
Moderate
Key labeling precautions relevant to this product, such as avoiding aspirin in severe renal failure (GFR <10 mL/min) and the stress testing interruption requirement (interrupt for 48 hours prior to pharmacological stress testing with IV dipyridamole/adenosinergic agents).
Importance:
Moderate
Contraindications for this product (e.g., hypersensitivity to components; aspirin contraindications for NSAID allergy/asthma rhinitis nasal polyps; avoid aspirin in children/teenagers with viral infections due to Reye syndrome).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The majority of statements are not supported by the provided label excerpts and repeatedly assert naproxen-specific interaction/symptom guidance. The only clearly supported safety point is general increased bleeding risk with this aspirin+extended-release dipyridamole product (and with other bleeding-risk drugs), which is insufficient to justify the detailed naproxen/acetaminophen guidance made.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Large number of claims about aspirin+naproxen and acetaminophen are unsupported by the provided FDA label excerpts for aspirin and extended-release dipyridamole; detailed symptom/timing guidance is not present.
Suggested Improvement
Limit claims to what is present in the provided label excerpts: product indication (reduce stroke risk post-TIA/completed ischemic stroke due to thrombosis), general bleeding risk, avoidance in severe renal failure (GFR <10 mL/min), contraindications, and any stated drug-interaction items relevant to this product (e.g., increased bleeding risk with anticoagulants/antiplatelet agents; stress testing interruption for IV dipyridamole/adenosinergic agents). Remove naproxen-specific and acetaminophen-specific assertions unless the corresponding label sections are provided.